View in EDS

Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.

Saved in:
Bibliographic Details
Title: Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
Authors: Kopmar NE; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Quach K; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Gooley TA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Martino CH; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Cherian S; Department of Laboratory Medicine and Pathology, University of Washington, Seattle., Percival MM; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Halpern AB; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Ghiuzeli CM; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Oehler VG; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Abkowitz JL; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Walter RB; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle., Cassaday RD; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
Source: JAMA oncology [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 961-965.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Medical Association Country of Publication: United States NLM ID: 101652861 Publication Model: Print Cited Medium: Internet ISSN: 2374-2445 (Electronic) Linking ISSN: 23742437 NLM ISO Abbreviation: JAMA Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38722664
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kopmar+NE%22">Kopmar NE</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Quach+K%22">Quach K</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Gooley+TA%22">Gooley TA</searchLink>; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Martino+CH%22">Martino CH</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Cherian+S%22">Cherian S</searchLink>; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.<br /><searchLink fieldCode="AU" term="%22Percival+MM%22">Percival MM</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Halpern+AB%22">Halpern AB</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Ghiuzeli+CM%22">Ghiuzeli CM</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Oehler+VG%22">Oehler VG</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Abkowitz+JL%22">Abkowitz JL</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.<br /><searchLink fieldCode="AU" term="%22Walter+RB%22">Walter RB</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.; Department of Laboratory Medicine and Pathology, University of Washington, Seattle.; Department of Epidemiology, University of Washington, Seattle.<br /><searchLink fieldCode="AU" term="%22Cassaday+RD%22">Cassaday RD</searchLink>; Division of Hematology-Oncology, Department of Medicine, University of Washington School of Medicine, Seattle.; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101652861%22">JAMA oncology</searchLink> [JAMA Oncol] 2024 Jul 01; Vol. 10 (7), pp. 961-965.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Medical+Association%22">American Medical Association </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101652861 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2374-2445 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223742437%22">23742437 </searchLink><i>NLM ISO Abbreviation: </i>JAMA Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38722664
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1001/jamaoncol.2024.0967
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 961
    Titles:
      – TitleFull: Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL: A Phase 1 Dose-Escalation Trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kopmar NE
      – PersonEntity:
          Name:
            NameFull: Quach K
      – PersonEntity:
          Name:
            NameFull: Gooley TA
      – PersonEntity:
          Name:
            NameFull: Martino CH
      – PersonEntity:
          Name:
            NameFull: Cherian S
      – PersonEntity:
          Name:
            NameFull: Percival MM
      – PersonEntity:
          Name:
            NameFull: Halpern AB
      – PersonEntity:
          Name:
            NameFull: Ghiuzeli CM
      – PersonEntity:
          Name:
            NameFull: Oehler VG
      – PersonEntity:
          Name:
            NameFull: Abkowitz JL
      – PersonEntity:
          Name:
            NameFull: Walter RB
      – PersonEntity:
          Name:
            NameFull: Cassaday RD
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2024 Jul 01
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2374-2445
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: JAMA oncology
              Type: main
ResultId 1